Research programme: HDL-related therapeutics - Esperion

Drug Profile

Research programme: HDL-related therapeutics - Esperion

Alternative Names: ESP-15228; HDL elevators

Latest Information Update: 24 Jun 2010

Price : $50

At a glance

  • Originator Esperion Therapeutics
  • Class Organic chemicals; Peptides; Small molecules
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Atherosclerosis; Dyslipidaemias

Most Recent Events

  • 22 Jun 2010 Esperion establishes technology supply agreement with TransGenRx
  • 16 Feb 2004 Esperion Therapeutics has been acquired by and merged into Pfizer
  • 10 Jun 2003 This programme is available for licensing [www.esperion.com]
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top